Breast Cancer

👀 217 patients with FGFR 1-4 alteration ➡️2 median prior systemic therapies 🚨ORR: 29.5% (Prior Therapy ORR 10%) ➡️Pancreatic cancer: 55.6% ➡️Biliary Tract Cancer: 51.6% ➡️Breast Cancer: 31% …. And many more @OncoAlert @VivekSubbiah @OncBrothers @curecc (@DrShubhamPant)

For me, I have restrained giving adjuvant chemotherapy to women over 60 with resected zero or few positive node breast cancer that was heavily ER positive. I thought Tamoxifen or AI was sufficient. Pretty much every other oncologist in town gave chemotherapy. Seemed excessive. (@davideyoungmd)

WATCH: @YAbdouMD, of @UNC_Lineberger, discusses updates in the treatment of patients with HR-positive, HER2-negative breast cancer. #bcsm #oncology https://t.co/bm3XbNunzN (@OncLive)

⁦@US_FDA⁩ ‘s Withdrawal of Later-Line Indication For #Olaparib in #BRCA Mutated #OvarianCancer ⁦@OncLive⁩ #gyncsm #womenshealth #cancerresearch #PARP https://t.co/MY9RghtCLp (@LguzzardiM)

Erika P. Hamilton, MD, discusses the role of T-DXd in HER2+ and HER2-low breast cancer, the evolution of CDK4/6 inhibitors in HR+ disease, and how genetic testing supports precision medicine research. @ErikaHamilton9 @SarahCannonDocs #bcsm #OncLiveIPC https://t.co/KYnlhERuBx (@OncLive)

The breast cancer tumor suppressor is called CDH1, not CHD1 (@PWBDerksen)

@JAMouabbi Interesting work! I wondered about TROP2 gene expression in lobular as I have seen some great responses to Saci. Would be cool to look at IHC. #bcsm (@drsarahsam)

Great discussion on HER2-low expression by 🌎 innovators of #breastcancer @BCJoyceO @TexasOncology & Dr. Sara Hurvitz @UCLAHealth 🎯 🧬 #wintheday (@chase_wasson)

⭐️ #ASCO23: "CAPItello-291 trial for Resistant HR+/HER2- Advanced Breast Cancer - Phase 3 Study with Hope Rugo, MD @hoperugo @UCSFCancer" 🔬Improved survival & well-tolerated adverse events in patients. #BreastCancer #cancercare 🎗️ [video] https://t.co/B4qiFs1ccT @OncoAlert (@oncologytube)

Sacituzumab Govitecan Wins Approval in Europe for Pretreated HR+/HER2– Metastatic Breast Cancer @JavierCortesMD @EU_Commission #bcsm https://t.co/3R7Nhoz78m (@OncLive)

🎥@ErikaHamilton9(@SarahCannonDocs) shares promising results from a Phase II trial of patritumab deruxtecan in metastatic breast cancer. HER3-DXd shows clinical activity and good tolerability: ➡️https://t.co/mq7yPFixUQ⬅️ #ASCO23 #BreastCancer #BCSM #ImmunoOnc (@VJOncology)

Just published in @TheACMG a guideline on clinical management of pathogenic CHEK2 variants and cancer risk. It was co-authored by @judithbalmana. ➕ https://t.co/NhCcqUL8Ke #breastcancer #cancergenetics #hereditarycancer (@VHIO)

Findings from phase 2 DAISY trial on T-DXd for #BreastCancer treatment demonstrated an ORR of 70.6% in HER2-overexpressing, 37.5% in HER2-low, and 29.7% in HER2 non-expressing tumors 📈 Read the #OpenAccess study in @NatureMedicine by @FerMosele, @FAndreMD and colleagues ➡️… https://t.co/k8JzPACWkv (@OncoViews)

Expanding Definitions of HER2 Expression Mediate the Role of ADCs in Breast Cancer @ErikaHamilton9 @PTarantinoMD @BurrisSkip @SarahCannonDocs @DanaFarber #bcsm #OncLiveIPC https://t.co/sPMkOpTjbz (@OncLive)

Radio day! Join me today 6-8pE on @SIRIUSXM 110 @NYUDocs for a great program-@heatherhcheng & @CureBRCA on #BRCA in men, the @PCFnews prostate segment on surgery & radiation w Dr Shore, disparities in #prostatecancer w @hypertensionmd &drug induced erectile problems w @MariaUloko (@LoebStacy)

Expanding Definitions of #HER2 Expression Mediate the Role of #ADCs in #BreastCancer https://t.co/zLa8sXu8ww via @onclive (@Rndubois)

The @oncoAlert 🚨Newsletter OUT TOMORROW: July 27, 2023 REGISTER📨to get it https://t.co/yzt83gqQkF Discussing: ✅DAISY🌼in #BreastCancer from @FAndreMD 🇫🇷 ✅RLY-4008 out on @CD_AACR by @VivekSubbiah 🇺🇸 ✅Obesity changes in #Breast Cancer from @ChristineDesme2 🇧🇪 ✅CA19-9… https://t.co/FbQ21kxRm9 (@OncoAlert)

"Virginia Kaklamani, MD @VKaklamani @UTHealthsaMDA discusses new data from #ASCO23 FDA-approved #Elacestrant for #breastcancer with ESR1-mutations. The EMERALD study results, announced by the #Menarini @Stemline Therapeutics, show PFS benefits. 🔬[video] https://t.co/9fioU5hFAU" (@oncologytube)

But.. this line, “Although T-DXd provides some clinical benefit in patients with HER2-overexpressing and HER2-low mBC, most of them will ultimately experience disease progression and die.” We need to change this outcome! #bcsm #metastaticbreastcancer #StageIVNeedsMore 😣 (@JaniceTNBCmets)

Continued research efforts have solidified the use of targeted therapies in HR-positive breast cancer and indicate the importance of further research with HER3-directed ADCs in metastatic disease. @maryam_lustberg @SmilowCancer @ASCO #ASCO23 #bcsm https://t.co/dJIGDZReL7 (@OncLive)

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. https://t.co/9ljWfZPHk0 @NatureMedicine @EdiBrogi @rovingatuscap @fcschmitt @TheISBP @LuisBlancoJrMD @PTarantinoMD (@HannahYWen)

Trastuzumab deruxtecan exhibits the highest objective response rate in patients with HER2+ metastatic #BreastCancer, but clinical activity is also observed in patients with HER2- or non-expressing tumors @fermosele @FAndreMD @GustaveRoussy #BCSM https://t.co/xciHmNO1wQ (@NatureMedicine)

🎥@MichaelGnant of @MedUni_Wien discusses late recurrences in ER-positive breast cancer at #ASCO23. Optimal treatment duration is 7-8 years, with 10 years for high-risk cases. The carryover effect brings long-lasting benefits: ➡️https://t.co/OG8RHYWG95⬅️ #BreastCancer #BCSM (@VJOncology)

Excellent panel discussion for Session IV on ER Positive Breast Cancer in the #HarvardBreastCancerCourse. #PabloLeone @PTarantinoMD @elmayermd @alex_toker @christinaminami @RMJesel @BeverlyMoy @drsarahsam (@DFCI_BreastOnc)

From Phase III KEYNOTE-826 to SHAPE and MIRASOL, our Dr. Shannon Westin discusses the results of these trials and what she is looking forward to seeing in gynecologic oncology. https://t.co/xeqnqTYq3s @OncLive @ShannonWestin #BreastCancer #GynCSM #EndCancer (@MDAndersonNews)

Tonight: Join Dr. Hope Rugo @hoperugo @UCSFCancer for the latest Bay Area Breast Cancer Forum discussing "Updates from the 2023 American Society of Clinical Oncology (#ASCO23) annual conference." Free & online https://t.co/eLjzy06ghC #bcsm #BreastCancer (@UCSFCancer)

The Harvard Breast Cancer Course has started with Monica Morrow doing an incredible job discussing how to manage the axilla @DFCI_BreastOnc @DrHBurstein #bcsm (@stolaney1)

Two years ago today I noticed a lump in my breast. If I’d been examining myself regularly, I might well have found it before the cancer spread to the sentinel lymph node. Please watch @Liz_ORiordan’s video and mark a date on the calendar to examine yourself monthly. #breastcancer (@SunshineScot)

Former breast cancer surgeon @Liz_ORiordan has said the NHS needs a MeToo movement because of sexual harassment in hospitals https://t.co/LiZVNnsmTy #breastsurgery #MeToo @BBCNews (@UKSurgeons)

This trend started in ENG yrs ago when HER2 drugs were first licensed for breast cancer. The ad agency paraded these miracle cases down the streets of Stoke (I think, off the top of my head). (@pash22)

The July issue of the #JITC Digest is here! View updates from Dr. Gulley and his picks of the latest immunotherapy research. Dive into a cutting-edge breast cancer discussion from the @edanzscience podcast featuring JITC's @RPatelMDPHD. Read more: https://t.co/eSF2GWKZPv (@sitcancer)

And don't miss the related commentary by @Matilde___ @matt_armi and @nicolobattisti: #SocialDeterminants of Health and Cardiac Risk for Patients With #BreastCancer: Beyond #RacialDisparities: https://t.co/JyxVBhbo15 #BCSM #SDOH #CardioOnc https://t.co/fXeUc0zyNf (@JNCCN)

ADCs have changed the way we treat breast cancer and there is much more to come – @Nader_Guilherme #cancer #article #biomarkers #cancerresearch #oncology #oncodaily https://t.co/Inu2cmSfiz (@oncodaily)

Congrats to @ASCO @jrgralow & the co-PIs on PCORI award. This clinical trial aims to improve care of older patients with metastatic breast cancer with CDK4/6 I. It builds ASCO’s commitment to health equity by ensuring all patients benefit from advances made in cancer treatment. (@ASCOPres)

Not necessarily I’ve been trying to use #bcsm (@Stickit2Stage4)

Thank you, @DrSGraff for your participation in this podcast to help patients with #cancer hear about the best of #ASCO23 in #breastcancer @OncoAlert (@arjazieh)

CCA's Sherry Hughes (@Sherry_Hughes) and Andy Guinigundo (@guiniga) welcome Dr. Stephanie Graff (@DrSGraff) to discuss the NATALEE Trial - one of the hottest topics discussed for #BreastCancer at @ASCO 2023. @arjazieh @CancerDotNet @ConquerCancerFd https://t.co/lPFyeMNVEK (@CancerAdvisors)

Please join @hoperugo @Dr_RShatsky @PTarantinoMD @Neil_Iyengar @AnnPartridgeMD @BCJoyceO myself and many others next week for an amazing program at the 22nd Annual International Congress on the Future of Breast Cancer® West in San Diego. Register now at: https://t.co/oNT5T8ifFZ (@hmcarthur)

It is for my 2 friends who have been diagnosed with cancer this year, and have died very quickly from it. One blood cancer (unclear which it was so fast) and one breast. You don’t go from symptomless to dead with breast cancer in your early 50s within 4 months usually. (@mumzles1)

A new @ASCO study, co-led by the HICCC's Dr. Dawn Hershman (@DrDawnHershman) has been awarded $11 million in research funding by @PCORI to study dosing strategies of oral CDK4/6 inhibitors in older adults living with metastatic breast cancer. @ColumbiaMed https://t.co/wQCQAVjBg7 (@columbiacancer)

Congratulations Dr. Erica Mayer @elmayermd and colleagues! This much needed study was designed using broad eligibility criteria and a pragmatic, patient-centric trial design in the hopes that the findings will guide treatment strategies for older patients with #BreastCancer. (@DFCI_BreastOnc)

Today @PCORI awarded $11M to @ASCO to study CDK4/6 inhibitor dosing in older patients w/metastatic breast cancer. Despite BC being more prevalent in people <65, few are included in current CDK4/6 trials. Study will be co-led by @elmayermd @DFCI_BreastOnc https://t.co/YYKIlCDYvf (@DanaFarberNews)